UPITTi002-A-1

iPSC Line

Provider

External iPSC Databases

General iPSC Information

• Barndt RJ et al. Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR/Cas9 editing. Stem cell research. 2021 Oct;56:102544.
• Dong M et al. CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases. Pharmacological research. 2022 Nov;185:106480.
• Barndt RJ et al. Metabolic Maturation Exaggerates Abnormal Calcium Handling in a Lamp2 Knockout Human Pluripotent Stem Cell-Derived Cardiomyocyte Model of Danon Disease. Biomolecules. 2022 Dec 29;13(1).
• Nandy Krittika et al. Efficient gene editing in induced pluripotent stem cells enabled by an inducible adenine base editor with tunable expression. Scientific Reports. 2023-12-11.
• Rahman S.M.. Opportunities and challenges for human microphysiological systems in drug development. ALTEX. 2024-00-00.
• Munshi Ingita Dey et al. Recent development in CRISPR-Cas systems for cardiac disease. Progress in Molecular Biology and Translational Science. 2025-00-00.
• Cavazza Alessia et al. Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group. Molecular Therapy Nucleic Acids. 2025-03-00.
• Gerritse Merel et al. Characteristics and pharmacological responsiveness in hiPSC models of inherited cardiomyopathy. Pharmacology & Therapeutics. 2025-08-00.
• Yu Qi et al. Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation. Advanced Science. 2026-02-00.

• UPITTi002-A

General